New president and CEO at Algeta
This article was originally published in Scrip
The Norwegian cancer therapeutics company Algeta has appointed Andrew Kay president and chief executive officer, effective January 19th. Dr Thomas Ramdahl, who has served as CEO since 2001, will become executive vice-president and chief technology officer. Mr Kay has more than 25 years' experience in the pharmaceutical sector, having previously served as executive director, commercial, at Renovo. He has also worked at Novartis, AstraZeneca, Lilly, Sandoz and Boots.